

Premiere for ZymIQ's oral care products in Asia – New distribution agreement for Thailand

ZymIQ Technology AB has signed an exclusive distribution agreement for its oral care products for humans with the Thai company Union Medical (Thailand) Co., Ltd. Previously, agreements have been signed in Thailand for the animal care segment.

Following the launch in February this year of its enzyme-based oral dissolving tablet, CombatClean™ Dental Enzyme Tab, ZymIQ has received significant attention. The product has previously been delivered and distributed to several NATO countries in Europe. The company has now also developed a consumer-adapted version of the enzyme tab under the DentaPrev™ brand as Clean Teeth Enzyme Tab. Together with the oral care spray, DentaPrev™ Dental Spray, they now form a product series for a daily oral care routine that cleans the mouth, reduces plaque, and promotes fresh breath.

Union Medical (Thailand) Co., Ltd., founded in 1976, is today one of the leading pharmaceutical importers and distributors in Thailand and has experienced strong growth in recent years. Its sales team operates nationwide and covers retail, pharmacy, and hospital segments.

“ZymIQ's products, with their unique solution to well-known oral health challenges, fit well into our product portfolio. The products have great potential in Thailand. We are therefore extremely pleased and highly motivated to launch these outstanding oral care products on our market and look forward to a successful collaboration” comments Yenchit Horveejkul, Group CEO, Union Medical (Thailand) Co., Ltd.

DentaPrev™ Clean Teeth Enzyme Tab is an enzyme-based tablet that dissolves in the mouth, designed to reduce plaque and biofilm formation. The product can be used as a complement to regular tooth brushing.

DentaPrev™ Dental Spray is an oral spray containing gentle ingredients with enzymes. It supports a healthy oral microbiome while reducing plaque and promoting fresh breath.

“Asia accounts for approximately 36% of the global oral care market, indicating significant growth opportunities for our products. We are very pleased with the strong interest and positive reception of our unique oral care products. Signing this agreement and being able to distribute both the consumer version of the enzyme tablet and the dental spray in Thailand as the first country makes me genuinely happy,” concludes Michael Edelborg Christensen, CEO of ZymIQ.

* Every care has been taken in the translation of this Press release. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information, please contact:

Michael Edelborg Christensen, CEO

Phone +46 727 144 166

Email: michael.christensen@zymiq.com

About ZymIQ

ZymIQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymIQ Group. Subsidiaries include ZymIQ Biopharma AB, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymIQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymIQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com

Attachments

[Premiere for ZymIQ's oral care products in Asia – New distribution agreement for Thailand](#)